Literature DB >> 21643035

Hepatitis: PEG-IFN for the treatment of hepatitis D.

Alessia Ciancio, Mario Rizzetto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21643035     DOI： 10.1038/nrgastro.2011.85

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  8 in total

1.  Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.

Authors:  Corinne Castelnau; Frédéric Le Gal; Marie-Pierre Ripault; Emmanuel Gordien; Michelle Martinot-Peignoux; Nathalie Boyer; Bach-Nga Pham; Sarah Maylin; Pierre Bedossa; Paul Dény; Patrick Marcellin; Elyanne Gault
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

2.  Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta.

Authors:  Grazia Anna Niro; Alessia Ciancio; Giovanni Battista Gaeta; Antonina Smedile; Aldo Marrone; Antonella Olivero; Maria Stanzione; Ezio David; Giuseppina Brancaccio; Rosanna Fontana; Francesco Perri; Angelo Andriulli; Mario Rizzetto
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

3.  Treatment of chronic hepatitis delta with pegylated interferon-alpha2b.

Authors:  Andreas Erhardt; Wolfram Gerlich; Christine Starke; Ulrike Wend; Andreas Donner; Abdurrahman Sagir; Tobias Heintges; Dieter Häussinger
Journal:  Liver Int       Date:  2006-09       Impact factor: 5.828

4.  Peginterferon plus adefovir versus either drug alone for hepatitis delta.

Authors:  Heiner Wedemeyer; Cihan Yurdaydìn; George N Dalekos; Andreas Erhardt; Yilmaz Çakaloğlu; Halil Değertekin; Selim Gürel; Stefan Zeuzem; Kalliopi Zachou; Hakan Bozkaya; Armin Koch; Thomas Bock; Hans Peter Dienes; Michael P Manns
Journal:  N Engl J Med       Date:  2011-01-27       Impact factor: 91.245

5.  Titration of the infectivity of hepatitis D virus in chimpanzees.

Authors:  A Ponzetto; B H Hoyer; H Popper; R Engle; R H Purcell; J L Gerin
Journal:  J Infect Dis       Date:  1987-01       Impact factor: 5.226

Review 6.  Hepatitis D: thirty years after.

Authors:  Mario Rizzetto
Journal:  J Hepatol       Date:  2009-02-04       Impact factor: 25.083

7.  Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.

Authors:  Patrizia Farci; Tania Roskams; Luchino Chessa; Giovanna Peddis; Anna Paola Mazzoleni; Rosetta Scioscia; Giancarlo Serra; Maria Eliana Lai; Maurizio Loy; Luciano Caruso; Valeer Desmet; Robert H Purcell; Angelo Balestrieri
Journal:  Gastroenterology       Date:  2004-06       Impact factor: 22.682

8.  Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon.

Authors:  C Yurdaydin; H Bozkaya; F O Onder; H Sentürk; H Karaaslan; M Akdoğan; H Cetinkaya; E Erden; O Erkan-Esin; K Yalçin; A M Bozdayi; R F Schinazi; J L Gerin; O Uzunalimoğlu; A Ozden
Journal:  J Viral Hepat       Date:  2008-04       Impact factor: 3.728
  8 in total
  2 in total

1.  Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.

Authors:  Joshua D Ochocki; Mark D Distefano
Journal:  Medchemcomm       Date:  2013-03       Impact factor: 3.597

2.  Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.

Authors:  Toni Herta; Magdalena Hahn; Melanie Maier; Janett Fischer; Johannes Niemeyer; Mario Hönemann; Albrecht Böhlig; Florian Gerhardt; Aaron Schindler; Jonas Schumacher; Thomas Berg; Johannes Wiegand; Florian van Bömmel
Journal:  Pathogens       Date:  2022-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.